Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
Year of publication: |
2022
|
---|---|
Authors: | Liu, Huiqin ; Wang, Ying ; He, Qi |
Published in: |
Health economics review. - Heidelberg : Springer, ISSN 2191-1991, ZDB-ID 2634483-X. - Vol. 12.2022, 1, Art.-No. 66, p. 1-10
|
Subject: | Non-small cell lung cancer | Sintilimab | Cost-efectiveness analysis | Partitioned survival model | Krebskrankheit | Cancer | China | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Gesundheitsökonomik | Health economics |
Description of contents: | Description [doi.org] |
Type of publication: | Article |
---|---|
Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
Language: | English |
Other identifiers: | 10.1186/s13561-022-00410-x [DOI] hdl:10419/285302 [Handle] |
Source: | ECONIS - Online Catalogue of the ZBW |
-
Barbier, Michaela Carla, (2021)
-
Holleman, Marscha S., (2020)
-
Liu, Huiqin, (2022)
- More ...
-
Liu, Huiqin, (2022)
-
Anticipatory event detection via classification
He, Qi, (2007)
-
He, Qi, (2015)
- More ...